<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03649984</url>
  </required_header>
  <id_info>
    <org_study_id>Symptom Navi© Pilot Study</org_study_id>
    <nct_id>NCT03649984</nct_id>
  </id_info>
  <brief_title>Implementation of the Symptom Navi© Program</brief_title>
  <official_title>Implementation of the Symptom Navi© Program for Cancer Patients in Ambulatory Services: A Cluster-randomized Pilot Study (Symptom Navi© Pilot Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manuela Eicher</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Lausanne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Symptom Navi© Program is a program to support symptom self-management of 16 core symptoms&#xD;
      frequently experienced by patients in outpatient oncology units.The current study aims to&#xD;
      pilot test the implementation of the Symptom Navi© Program under real-life conditions by&#xD;
      evaluating procedures, testing preliminary effectiveness and assessing potential unintended&#xD;
      effects using a cluster-randomised waitlist design complemented by qualitative methods.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients treated in cancer outpatient settings in Switzerland have high unmet care needs,&#xD;
      especially in the domain of self-management of symptoms. The Symptom Navi© Program was&#xD;
      developed to support symptom self-management of 16 core symptoms frequently experienced by&#xD;
      patients in outpatient oncology units. The acceptability and feasibility of the Symptom Navi©&#xD;
      Program was supported by a qualitative study with 10 cancer patients who received&#xD;
      semi-structured patient consultations and subsequently used the Symptom Navi© Flyers at home.&#xD;
&#xD;
      The overall objective of the current study is to pilot test the implementation of the Symptom&#xD;
      Navi© Program under real-life conditions. The aims are to evaluate procedures, to test&#xD;
      preliminary effectiveness and to assess potential unintended effects using a&#xD;
      cluster-randomised waitlist design complemented by qualitative methods. The unit of&#xD;
      randomization are the participating cancer outpatient centres with each centre representing a&#xD;
      cluster. Intervention cluster will provide the Symptom Navi© Program, control clusters will&#xD;
      provide usual care for symptom-management.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Actual">April 12, 2019</completion_date>
  <primary_completion_date type="Actual">April 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>cluster-randomized waitlist design</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in patient-reported symptom interference with daily function</measure>
    <time_frame>Change from baseline to 16 weeks</time_frame>
    <description>Symptom interference with daily function in the affective and activity subdimension scores of the MD Anderson Symptom Inventory (MDASI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reach of intervention in terms of proportion of eligible vs. participating patients</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient-reported self-efficacy</measure>
    <time_frame>Change from baseline to 16 weeks</time_frame>
    <description>Self-efficacy assessed by the Self-Efficacy for Managing Chronic Disease (SES6G)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient-reported symptom severity</measure>
    <time_frame>Change from baseline to 16 weeks</time_frame>
    <description>Symptom severity assesssed by the MD Anderson Symptom Inventory (MDASI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient-reported quality of nursing care</measure>
    <time_frame>Change from baseline to 16 weeks</time_frame>
    <description>Quality of nursing care assessed by the Patient-Reported Chemotherapy Indicators of Symptoms and Experiences (PR-CISE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Intervention-Emergent Adverse Events</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Symptom Navi© Program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nurses provide two semi-structured consultation to facilitate basic symptom self-management of patients based in the Symptom Navi© Flyers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care including information about treatment, potential side effects and expected symptoms under treatment with or without additional written material following the established procedure at the centre.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Symptom Navi© Program</intervention_name>
    <description>Trained nurses provide two semi-structured patient education consultations with Symptom Navi© Flyers. Patients will use the Symptom Navi© Flyers individually at home.</description>
    <arm_group_label>Symptom Navi© Program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for patients:&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  newly diagnosed with cancer within 15 weeks prior to informed consent signature&#xD;
&#xD;
          -  planned to receive first cycle of their first-line pharmacological anti-cancer&#xD;
             treatment in an outpatient centre (intravenous, oral or subcutaneous)&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria for patients:&#xD;
&#xD;
          -  not sufficiently literate in German language to understand written information or&#xD;
             follow an interview&#xD;
&#xD;
          -  recurrence of cancer disease&#xD;
&#xD;
          -  cared by a palliative care team&#xD;
&#xD;
          -  being treated solely with surgical or radiation therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuela Eicher, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>UniLausanne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynäkologisches Tumorzentrum Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncocare, Klinik Engeried Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital fribourgeois - Meyriez-Murten / Tagers</name>
      <address>
        <city>Murten</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tumor- und Brustzentrum ZeTuP Rapperswil</name>
      <address>
        <city>Rapperswil</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rundum Onkologie am Bahnhofpark Sargans</name>
      <address>
        <city>Sargans</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solothurner Spitäler AG - Kantonsspital Olten / Bürgerspital Solothurn</name>
      <address>
        <city>Solothurn</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spital STS AG - Thun</name>
      <address>
        <city>Thun</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>August 21, 2020</last_update_submitted>
  <last_update_submitted_qc>August 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne</investigator_affiliation>
    <investigator_full_name>Manuela Eicher</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Symptom-management</keyword>
  <keyword>Outpatients</keyword>
  <keyword>Nurse-led intervention</keyword>
  <keyword>Implementation</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

